Cantor Fitzgerald Research Analysts Lift Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Equities researchers at Cantor Fitzgerald upped their FY2019 earnings per share estimates for shares of Jazz Pharmaceuticals in a research note issued on Wednesday, November 6th. Cantor Fitzgerald analyst B. Folkes now expects that the specialty pharmaceutical company will earn $14.02 per share for the year, up from their prior forecast of $13.43.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The business had revenue of $537.70 million during the quarter, compared to analysts’ expectations of $523.92 million. During the same quarter in the prior year, the business posted $3.58 earnings per share. Jazz Pharmaceuticals’s revenue was up 14.6% compared to the same quarter last year.
JAZZ opened at $130.14 on Friday. The stock has a market capitalization of $7.24 billion, a price-to-earnings ratio of 10.63, a P/E/G ratio of 1.57 and a beta of 1.09. The company has a 50-day simple moving average of $124.77 and a 200 day simple moving average of $131.70. The company has a quick ratio of 3.52, a current ratio of 3.71 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a twelve month low of $113.52 and a twelve month high of $154.44.
In related news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total value of $65,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Paul Treacy sold 4,371 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,371 shares of company stock worth $730,575. 4.30% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 2.2% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 457,226 shares of the specialty pharmaceutical company’s stock worth $65,183,000 after purchasing an additional 9,797 shares in the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $324,000. CENTRAL TRUST Co lifted its stake in Jazz Pharmaceuticals by 256.4% during the 2nd quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock valued at $210,000 after acquiring an additional 1,095 shares in the last quarter. Chicago Equity Partners LLC lifted its stake in Jazz Pharmaceuticals by 152.4% during the 2nd quarter. Chicago Equity Partners LLC now owns 16,760 shares of the specialty pharmaceutical company’s stock valued at $2,389,000 after acquiring an additional 10,120 shares in the last quarter. Finally, Zacks Investment Management bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at $1,626,000. Institutional investors own 87.71% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: What are no-load funds?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.